Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience
Andrew Schaefer(University of Wisconsin–Madison), Basem M. William(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Adam S. Kittai(The Ohio State University Wexner Medical Center), Samantha Jaglowski(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Ying Huang(Marshall University), Ayman Saad(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Joseph Maakaron(University of Minnesota), Jonathan E. Brammer(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Caner Saygin(University of Chicago), Sam Penza(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute)
Cited by 24
Related Papers
Short-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer (RELARC): a randomised, controlled, phase 3, superiority trial
|The Lancet Oncology|2021|184
Immune Checkpoint Inhibitors in Organ Transplant Patients
|Journal of Immunotherapy|2017|150
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016
|Journal of the National Comprehensive Cancer Network|2016|141
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia
|JACC CardioOncology|2023|107
Diffuse Large B-Cell Lymphoma Version 1.2016
|Journal of the National Comprehensive Cancer Network|2016|87